SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: ...

Tonight, look up in the sky. Look east and you will see the moon and Regulus unite, giving all of the residents of Earth (who are keen on stargazing) a unique concert. This concert begins in the ...

Maybe the third time's the charm? Regulus Therapeutics is once again shuffling its pipeline and sliding a new kidney disease candidate into the high-priority queue, hoping for better fortunes after a ...

Regulus (NASDAQ:RGLS) Therapeutics Inc., a biopharmaceutical company, has entered into a significant licensing agreement with The University of Texas System on behalf of The University of Texas at ...

Mercury passes 1.2° north of Regulus at 6 A.M. EDT; the pair is visible in the east just before sunrise, but it might be a challenging observation. You’ll want to get to a location above the ...

Sanofi is letting go of a genetic kidney disease therapy under development with Regulus Therapeutics after getting a peak at an interim analysis. Development will be shut down for the anti-microRNA 21 ...

Regulus (RGLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most ...